MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-AP-10-0017824
Genome Therapeutics Private Limited
Genome Therapeutics Private Limited - pharma in Secunderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹5.47 Cr
▲ 14% YoY
Net profit · FY 2025
₹54.94 Lakh
Net margin 10%
EBITDA · FY 2025
₹85.05 Lakh
EBITDA margin 15.5%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹10 Lakh
Issued & subscribed
Open charges
₹63 Lakh
Secured borrowings
Company age
15 yrs
Est. 2011
Directors on board
2
As per MCA filings
About Genome Therapeutics Private Limited
Data last updated:
Genome Therapeutics Private Limited is a private limited company based in Secunderabad, Telangana, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 15 July 2011 and has been in existence for over 15 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2011PTC075543. Its GSTIN is 37AAECG4593R1ZQ (Andhra Pradesh). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Dhavala Madhavi (Managing Director) and Ravimohan Dhavala (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H.No: 1 – 18 – 76/1/F2 Vijay Residency Mes Colony Venkatapuram, Secunderabad, Telangana, India – 500015.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.47 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net profit of ₹54.94 Lakh (net margin 10%) and EBITDA of ₹85.05 Lakh (EBITDA margin 15.5%). Revenue has grown at a compounded annual rate (CAGR) of 17% over three years and 15% over five years.
As per MCA filings, the company has open charges of ₹63 Lakh on record.
Genome Therapeutics Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-AP-10-0017824). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U24232TG2011PTC075543
Registration Number 075543
Incorporation Date 15 July 2011
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-AP-10-0017824
CIN history
Genome Therapeutics has one previous CIN (Corporate Identification Number): U24232AP2011PTC075543. The current CIN is U24232TG2011PTC075543, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2011PTC075543 | Current |
| U24232AP2011PTC075543 | Previous |
Recognitions & Rankings of Genome Therapeutics
Contact details
Genome Therapeutics Private Limited's registered office is in Secunderabad, Telangana. Its e-mail address is in the company report.
- Email
- Registered AddressH.No: 1 – 18 – 76/1/F2 Vijay Residency Mes Colony Venkatapuram, Secunderabad, Telangana, India – 500015
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Genome Therapeutics Private Limited, buy the company report.
Comprehensive company report
Genome Therapeutics Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Genome Therapeutics is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Genome Therapeutics Private Limited, buy the company report.
Financials of Genome Therapeutics Private Limited
FY 2025 filings availableGenome Therapeutics Private Limited reported revenue of ₹5.47 Cr (up 14% YoY) for FY 2025.
Revenue · FY 2025
₹5.47 Cr ▲ 14%
Net profit · FY 2025
₹54.94 Lakh margin 10%
EBITDA · FY 2025
₹85.05 Lakh margin 15.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 14%
3 years · compounded
▲ 17%
5 years · compounded
▲ 15%
EBITDA CAGR growth
1 year
▲ 125%
3 years · compounded
▲ 49%
5 years · compounded
▲ 36%
Revenue has grown at a compounded annual rate (CAGR) of 15% over five years, including 14% growth in the latest year. EBITDA rose 125% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹85.05 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹54.94 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.5% | ||||
| Net Profit Margin | 10% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Genome Therapeutics Private Limited, buy the company report.
Board of directors of Genome Therapeutics Private Limited
Genome Therapeutics has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dhavala Madhavi | Managing Director | 15 Jul 2011 | 15 Years 3 Months | Current |
| Ravimohan Dhavala | Whole-Time Director | 15 Jul 2011 | 15 Years 3 Months | Current |
Peer comparison
Genome Therapeutics Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aviator Life Science Private Limited | ₹5.49 Cr (FY 2025) | 14.0% | Ahmedabad, Gujarat, India | |||
| Emdrix Pharmaceuticals Private Limited | ₹5.48 Cr (FY 2017) | 73.0% | Bangalore, Karnataka, India | |||
| Pee Vee Products Private Limited | ₹5.48 Cr (FY 2025) | 14.0% | Ahmedabad, Gujarat, India | |||
| Genome Therapeutics Private Limitedthis company | ₹5.47 Cr (FY 2025) | ₹54.94 Lakh | 10% | 14.0% | Secunderabad, Telangana, India | |
| Medolway Life Sciences Private Limited | ₹5.47 Cr (FY 2025) | -12.0% | Ambala Cantt, Haryana, India |
To see the full peer comparison of Genome Therapeutics Private Limited, buy the company report.
Auditor
Genome Therapeutics Private Limited is audited by DHANUNJAYA & HARANATH for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DHANUNJAYA & HARANATH | FY 2020 | 014288S |
Shareholding
The shareholding of Genome Therapeutics Private Limited is on record for 4 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Genome Therapeutics Private Limited, buy the company report.
Charges & borrowings
Open charges
₹63 Lakh
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Dec 2012 | 10446105 | Others | ₹63 Lakh | Open |
To see the full charge records of Genome Therapeutics Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Genome Therapeutics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Genome Therapeutics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Genome Therapeutics has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 37AAECG4593R1ZQ | Andhra Pradesh | Active | 27 Jan 2019 |
To see the full GST registrations and return filing status of Genome Therapeutics Private Limited, buy the company report.
Recent activity
Genome Therapeutics Private Limited has 6 board changes on record since 2011: 2 appointments and 4 cessations. The latest: Dhavala Madhavi ceased to be Director on 27 Dec 2018.
AGM
Genome Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Genome Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Dhavala Madhavi ceased to be Director.
Ceased
Ravimohan Dhavala ceased to be Director.
Ceased
Dhavala Venkata Suryanarayana Sarma ceased to be Director.
Charges
A charge with Others of Rs. 63.00 Lakh registered on 08 Dec 2012 with Charge ID 10446105 was modified on 23 Jun 2016.
Ceased
Suman Kumar Araveti ceased to be Director.
Charges
A charge with Others amounted to Rs. 63.00 Lakh with Charge ID 10446105 was registered on 08 Dec 2012.
Appointed
Dhavala Madhavi was appointed as Managing Director.
Appointed
Ravimohan Dhavala was appointed as Whole-Time Director.
Incorporation
15 Jul 2011
Genome Therapeutics Private Limited was registered on 15 Jul 2011 with Roc Hyderabad & aged 15 years 3 months as per MCA records.
Frequently asked questions
Genome Therapeutics is an active private limited company based in Secunderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 15 July 2011 (15+ years old) and is registered under CIN U24232TG2011PTC075543.
Genome Therapeutics has 2 current directors:
- Dhavala Madhavi - Managing Director
- Ravimohan Dhavala - Whole-Time Director
The latest financial statements of Genome Therapeutics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Genome Therapeutics is 37AAECG4593R1ZQ, registered in Andhra Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Genome Therapeutics is U24232TG2011PTC075543. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Genome Therapeutics was incorporated on 15 July 2011, making it 15+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Genome Therapeutics by revenue are Aviator Life Science Private Limited, Emdrix Pharmaceuticals Private Limited, Pee Vee Products Private Limited, Medolway Life Sciences Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Dhavala Madhavi ceased to be Director on 27 Dec 2018. Ravimohan Dhavala ceased to be Director on 27 Dec 2018. Dhavala Venkata Suryanarayana Sarma ceased to be Director on 16 Aug 2018. Genome Therapeutics has 6 board changes on record in total.
Yes, Genome Therapeutics is registered as a micro enterprise under Udyam registration (number: UDYAM-AP-10-0017824).
The registered office of Genome Therapeutics is at H.No: 1 – 18 – 761F2 Vijay Residency Mes Colony Venkatapuram, Secunderabad, Telangana, India – 500015.
Genome Therapeutics operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages